Compare RGS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | SNTI |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 53.6M |
| IPO Year | 1991 | N/A |
| Metric | RGS | SNTI |
|---|---|---|
| Price | $27.74 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 10.4K | ★ 99.2K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.05 | N/A |
| EPS | ★ 45.08 | N/A |
| Revenue | ★ $223,032,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | $0.64 | ★ N/A |
| Revenue Growth | ★ 13.98 | N/A |
| 52 Week Low | $15.00 | $1.26 |
| 52 Week High | $31.50 | $7.25 |
| Indicator | RGS | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 55.97 |
| Support Level | $26.57 | $2.03 |
| Resistance Level | $29.04 | $2.25 |
| Average True Range (ATR) | 0.69 | 0.17 |
| MACD | 0.25 | 0.03 |
| Stochastic Oscillator | 88.44 | 85.20 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.